| Pegasys (pegylated interferon α -2a) / Roche |
ACTRN12605000041651: Phase II trial of Pegasys in Glivec responsive chronic phase chronic myeloid leukaemia |
|
|
| Completed | 2 | 60 | | | Australasian Leukaemia and Lymphoma Group, Novartis Australia, Roche Australi | Chronic myeloid leukaemia | | | | |
AFR07, NCT00763763: Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive |
|
|
| Completed | 2 | 55 | Europe | Imatinib mesylate, Interferon, Pegasys, Interferon, Pegasys, Vincristine, Dexamethasone | Assistance Publique - Hôpitaux de Paris | Leukemia, Lymphocytic, Acute, Philadelphia Chromosome, Blast Crisis, Leukemia, Myeloid, Chronic | 10/07 | 01/10 | | |
NCT01392170: Pegasys in Patients With Chronic Myeloid Leukemia (CML) |
|
|
| Terminated | 2 | 2 | US | PEG-IFNá-2a, Pegasys, Peginterferon Alpha-2a | M.D. Anderson Cancer Center | Leukemia | 03/14 | 03/14 | | |
NCT00452023: Pegasys® in Patients With Myeloproliferative Diseases |
|
|
| Completed | 2 | 84 | US | IFN-alpha2a, Pegylated-Interferon Alpha-2A, PEG-IFNa-2a, Pegasys | M.D. Anderson Cancer Center | Myeloproliferative Disorders | 05/23 | 05/23 | | |
NCT00962715: Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia |
|
|
| Withdrawn | 1/2 | 0 | US | Influenza Vaccine Trivalent Inactivated (TIV), Pegylated interferon (PEGrIFN-α, Pegasys), Pegasys, Peginterferon alfa-2a, Interferon (IFNα, Roferon-A), Roferon-A, Interferon alfa-2a | M.D. Anderson Cancer Center | Chronic Lymphocytic Leukemia | | | | |
NCT02328755: Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia |
|
|
| Completed | 1/2 | 37 | US | peg-IFN-α, PEGASYS®, Hematopoietic Cell Transplant (HCT), Tacrolimus, Methotrexate | University of Michigan Rogel Cancer Center | Acute Myeloid Leukemia | 03/19 | 03/19 | | |
